BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, Bonanni P. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother 2013;9:1119-28. [PMID: 23376840 DOI: 10.4161/hv.23827] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Bencina G, Bento-Abreu A, Sabale U, Tsoumani E, Laigle V, Dauby N, Ethgen O, Salomonsson S. Estimating the lifetime cost of vaccination in 23 European Countries: a modeling study. Expert Rev Vaccines 2023;22:148-60. [PMID: 36519294 DOI: 10.1080/14760584.2023.2157266] [Reference Citation Analysis]
2 Boccalini S, Bonito B, Zanella B, Liedl D, Bonanni P, Bechini A. The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile. Int J Environ Res Public Health 2022;19. [PMID: 36498435 DOI: 10.3390/ijerph192316365] [Reference Citation Analysis]
3 Liu Z, Li M, Hutton DW, Wagner AL, Yao Y, Zhu W, Cao L, Tang S, Pan J, Wang Y, Zhao Q, Ren H, Wang Y, Wang W. Impact of the national hepatitis B immunization program in China: a modeling study. Infect Dis Poverty 2022;11:106. [PMID: 36221140 DOI: 10.1186/s40249-022-01032-5] [Reference Citation Analysis]
4 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 53.0] [Reference Citation Analysis]
5 Netanel C, Ben-Aharon O, Ben-Ari Z, Chodick G, Anis E, Magnezi R. Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016. Vaccine 2021;39:7101-7. [PMID: 34782158 DOI: 10.1016/j.vaccine.2021.09.072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Pinon M, Giugliano L, Nicastro E, Kakaa O, Coscia A, Carbonara C, D'Antiga L, Calvo PL. Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy. Vaccines (Basel) 2021;9:801. [PMID: 34358216 DOI: 10.3390/vaccines9070801] [Reference Citation Analysis]
7 Mokhtari AM, Barouni M, Moghadami M, Negahdaripour M, Mirahmadizadeh A. Estimating costs of hepatitis B vaccination in infants: experimental evidence of the expanded program on immunization in Southern Iran. J Public Health (Oxf) 2021:fdab118. [PMID: 33866375 DOI: 10.1093/pubmed/fdab118] [Reference Citation Analysis]
8 Bechini A, Bonanni P, Grazzini M, Paolini D, Arcangeli G, Mucci N, Bini C, Tiscione E, Zanella B, Boccalini S. Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients. Hum Vaccin Immunother 2021;17:580-2. [PMID: 33270480 DOI: 10.1080/21645515.2020.1810495] [Reference Citation Analysis]
9 Guo Y, Yang Y, Bai Q, Huang Z, Wang Z, Cai D, Li S, Man X, Shi X. Cost-utility analysis of newborn hepatitis B immunization in Beijing. Hum Vaccin Immunother 2021;17:1196-204. [PMID: 33016814 DOI: 10.1080/21645515.2020.1807812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Upala P, Apidechkul T, Tamornpark R, Chomchoei C, Yeemard F. Seroprevalence and factors associated with hepatitis B infection among the hill tribe adult population in Thailand: a cross-sectional study. BMC Infect Dis 2020;20:494. [PMID: 32650741 DOI: 10.1186/s12879-020-05221-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Moghadami M, Dadashpour N, Mokhtari AM, Ebrahimi M, Mirahmadizadeh A. The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study. Braz J Infect Dis 2019;23:419-26. [PMID: 31678055 DOI: 10.1016/j.bjid.2019.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Borràs E, Urbiztondo L, Carmona G, Jané M, Barrabeig I, Rosa Sala M, Jorgina Balañà JP, Company M, Parrón I, Godoy P, Rius C, Soldevila N, Cabezas C, Domínguez À; Working Group for the Study of Hepatitis B in Catalonia. Effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia 21 years after its introduction. Vaccine 2019;37:1137-41. [PMID: 30709729 DOI: 10.1016/j.vaccine.2019.01.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Bianchi FP, Gallone MS, Gallone MF, Larocca AMV, Vimercati L, Quarto M, Tafuri S. HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: An Italian study among medical students. J Viral Hepat 2019;26:136-44. [PMID: 30199579 DOI: 10.1111/jvh.13001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
14 Dusheiko G, Agarwal K. Delineating the global challenges of hepatitis B virus infection. Lancet Gastroenterol Hepatol 2018;3:372-3. [PMID: 29599077 DOI: 10.1016/S2468-1253(18)30093-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Boa A, Douba A, Menan H, Attia A, Ouassa T, Bénié JBV, Abokon A, Dosso M, Aholi P, Timité-konan M, Abauleth RY, Bissagnéné E, Aka J, Yavo JC, Sylvain BJ, Ouattara GS, Ekra DK, Sow K, Kouassi JN, Kouakou Ahoussou ÉM, Dally RK. Plaidoyer pour l’introduction du vaccin contre l’hépatite virale B à la naissance en Côte d’Ivoire. Santé Publique 2017;Vol. 29:751-760. [DOI: 10.3917/spub.175.0751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Zhou Y, He H, Deng X, Yan R, Tang X, Xie S, Yao J. Significant reduction in notification and seroprevalence rates of hepatitis B virus infection among the population of Zhejiang Province, China, aged between 1 and 29years from 2006 to 2014. Vaccine 2017;35:4355-61. [PMID: 28687404 DOI: 10.1016/j.vaccine.2017.06.078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return on investment of public health interventions: a systematic review. J Epidemiol Community Health 2017;71:827-34. [PMID: 28356325 DOI: 10.1136/jech-2016-208141] [Cited by in Crossref: 173] [Cited by in F6Publishing: 176] [Article Influence: 28.8] [Reference Citation Analysis]
18 Ramière C, Roche L, Scholtès C, Iwaz J, Saison J, Ecochard R, André P. Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994. Clin Microbiol Infect 2016;22:889.e1-7. [PMID: 27451939 DOI: 10.1016/j.cmi.2016.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Yu L, Wang J, Wangen KR, Chen R, Maitland E, Nicholas S. Factors associated with adults' perceived need to vaccinate against hepatitis B in rural China. Hum Vaccin Immunother 2016;12:1149-54. [PMID: 27042968 DOI: 10.1080/21645515.2015.1132964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Gibson E, Begum N, Sigmundsson B, Sackeyfio A, Hackett J, Rajaram S. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review. Hum Vaccin Immunother 2016;12:1202-16. [PMID: 26837602 DOI: 10.1080/21645515.2015.1131369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wang Z, Li M, Wang P, Yang Z, Wei L, Zeng Y, Li Y, Yan L, Liu X, Zhuang H. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China. Vaccine 2016;34:1034-9. [DOI: 10.1016/j.vaccine.2016.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Gasparini R, Mennini FS, Panatto D, Bonanni P, Bechini A, Ricciardi W, DE Waure C, Marcellusi A, Cicchetti A, Ruggeri M, Boccalini S. How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project. J Prev Med Hyg 2015;56:E150-4. [PMID: 26900329] [Reference Citation Analysis]
23 Rémy V, Zöllner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy 2015;3. [PMID: 27123189 DOI: 10.3402/jmahp.v3.27041] [Cited by in Crossref: 53] [Cited by in F6Publishing: 68] [Article Influence: 6.6] [Reference Citation Analysis]
24 . The Economic Value of Vaccination: Why Prevention is Wealth. J Mark Access Health Policy 2015;3. [PMID: 27123186 DOI: 10.3402/jmahp.v3.29414] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Lugoboni F, Pavarin RM, Resentera C, Gambini D. Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users. Int J Environ Res Public Health 2015;12:3979-92. [PMID: 25872013 DOI: 10.3390/ijerph120403979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Orlando R, Foggia M, Maraolo AE, Mascolo S, Palmiero G, Tambaro O, Tosone G. Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis. 2015;34:1059-1070. [PMID: 25678010 DOI: 10.1007/s10096-015-2341-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
27 Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013;59:1363-4. [PMID: 23994385 DOI: 10.1016/j.jhep.2013.08.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]